Lumen apposing stent to deliver targeted therapy

Abstract

To provide a device, a system, and a method for reducing or preventing movement of an expanded stent.SOLUTION: A device, a system, and a method for delivering targeted therapy to tissue at a treatment site with the use of a stent 210 are provided. The targeted therapy may include a functional and / or therapeutic agent 150 separate from the stent, or a component of a functional and / or therapeutic agent separate from the stent and reactive with another component of a functional and / or therapeutic agent on the stent. The agent or component of an agent may be delivered with the stent, and / or before delivery of the stent, and / or after the stent has been delivered.SELECTED DRAWING: Figure 2B

Description

[Technical Field]

[0001] The present disclosure relates generally to the field of medical devices, systems, and methods for operatively delivering functional and / or therapeutic agents to the body, such as body tissue. More particularly, the present disclosure relates to medical devices, systems, and methods that utilize a device as a scaffold upon which functional and / or therapeutic agents can be deposited and delivered, such as in situ, to the body. [Background technology]

[0002] Various implantable devices are used in multiple therapeutic protocols and procedures. For example, stents, such as self-expanding metallic stents (SEMS), can be used within anatomical regions (e.g., body lumens, passageways, blood vessels, ducts, etc.) to enable fluid communication from one region to another, such as through a body lumen, or from one anatomical structure (e.g., a body lumen or cavity or organ) to another anatomical structure (e.g., a body lumen or cavity or organ). Stents, such as luminal apposing stents, can be used to increase and improve access to different anatomical regions, such as within the gastrointestinal (GI) tract. Current uses of luminal apposing stents include drainage of pancreatic pseudocysts and antegrade access to the gallbladder. Stents can also be used to hold body tissues in apposition. One challenge faced when using stents is that various forces (e.g., as a result of the patient's natural movements or involuntary movements within the body, such as peristalsis along the GI tract) can increase the risk of stent migration. Migration of an implanted stent can result in fluid leakage, patient discomfort, and / or additional procedures to replace the stent. Therefore, various devices, systems, and methods for reducing or preventing migration of deployed stents would be welcomed in the industry. Furthermore, expanded use of stents for full-thickness resection closure, etc., by addressing various challenges presented by such procedures would also be welcomed in the industry. Finally, various safe and efficient mechanisms for applying drugs or substances to the stent target / deployment site during or after deployment would also be welcomed in the industry. Summary of the Invention

[0003] This Summary of the disclosure is provided to aid in understanding, and those skilled in the art will appreciate that each of the various aspects and features of the disclosure may be used advantageously separately in some instances or in combination with other aspects and features of the disclosure in other instances. No limitation as to the scope of the claimed subject matter is intended by the inclusion or non-inclusion of elements, components, etc. in this Summary.

[0004] According to one aspect of the present disclosure, a system for maintaining a flow path in tissue includes a first sheath, a stent disposed within the first sheath, and a second sheath disposed about the first sheath. In some embodiments, the stent is configured to transition between a first configuration and a second configuration. In some embodiments, a functional and / or therapeutic agent is disposed between the first sheath and the second sheath.

[0005] In some embodiments, the functional and / or therapeutic agent comprises an agent selected from the group comprising adhesives, healing agents, and therapeutic agents. In some embodiments, the stent is disposed about the inner member, and the first sheath is longitudinally retractable proximally relative to the inner member, or the inner member is longitudinally extendable distally relative to the first sheath, or both, such that the stent is released from within the first sheath and transitions to the second configuration.

[0006] In some embodiments, a first functional and / or therapeutic agent component is disposed between the first sheath and the second sheath, and a second functional and / or therapeutic agent component is disposed on the stent when disposed within the first sheath.

[0007] According to another aspect of the present disclosure, a system is disclosed having a stent including a lumen extending longitudinally therethrough and configured to shift between a first configuration and a second configuration, and a functional and / or therapeutic agent. In some embodiments, in the second configuration, the stent defines a first retention member, a second retention member, and a saddle region extending therebetween, and when the stent is deployed in the body lumen in the second configuration, the first retention member, the second retention member, the saddle region, and the tissue wall of the body lumen define a volume configured to retain the functional and / or therapeutic agent therein.

[0008] In some embodiments, the first and second retention members are configured to space tissue away from the saddle region. In some embodiments, the functional and / or therapeutic agent comprises an agent selected from the group comprising adhesives, healing agents, functional or therapeutic agents.

[0009] In some embodiments, the system further includes a fluid delivery device configured to inject a functional and / or therapeutic agent. In some embodiments, the fluid delivery device is configured to inject the functional and / or therapeutic agent through the tissue wall and into a volume defined by the stent and the tissue wall. In some embodiments, the fluid delivery device is configured to extend through one of the first retention member or the second retention member and inject the functional and / or therapeutic agent into the volume defined by the stent and the tissue wall.

[0010] In some embodiments, the stent further comprises another functional and / or therapeutic agent disposed therealong. According to another aspect of the present disclosure, a method of forming an anastomosis includes advancing a delivery system from a first lumen across a first tissue and a second tissue and into a second lumen. In some embodiments, the delivery system includes a first sheath, an inner member, a stent disposed within and about the first sheath, a second sheath disposed about the first sheath, and a functional and / or therapeutic agent disposed between the first and second sheaths. In some embodiments, the stent is configured to transition between a first configuration and a second configuration. In some embodiments, the method also includes retracting the first and second sheaths proximally relative to the inner member, extending the inner member distally relative to the first and second sheaths, or both, such that a first end of the stent extends distally outside the first sheath and forms a first retention member within the second body lumen, and the functional and / or therapeutic agent is disposed on a surface of the stent. In some embodiments, the method further includes retracting the first sheath proximally relative to the inner member, or extending the inner member distally relative to the first sheath, or both, such that the second end of the stent is unconstrained from the first sheath and forms a second retention member within the first body lumen.

[0011] In some embodiments, the method further includes disposing a functional and / or therapeutic agent on a surface of the saddle region of the stent during proximal retraction of the first sheath relative to the inner member, or distal extension of the inner member relative to the first sheath, or both.

[0012] In some embodiments, the method further includes disposing a functional and / or therapeutic agent on a surface of the second retention member upon proximally retracting the first sheath relative to the inner member, or distally extending the inner member relative to the first sheath, or both.

[0013] In some embodiments, the method further comprises disposing additional functional and / or therapeutic agents along the surface of the saddle region. In some embodiments, placing the additional functional and / or therapeutic agent comprises injecting the additional functional and / or therapeutic agent through a needle.

[0014] In some embodiments, the inner member includes a cutting element disposed at an end thereof, and the method further includes forming an anastomosis across the first tissue and the second tissue with the cutting element before extending the first end of the stent distally outside the first sheath. [Brief explanation of the drawings]

[0015] Non-limiting examples of the present disclosure will be described with reference to the accompanying drawings, which are schematic and not intended to be drawn to scale. In the drawings, each of the identical or nearly identical components shown is typically represented by a single numeral. For clarity, not every component is labeled in every drawing, and not every component in each embodiment of the present disclosure is shown unless illustration is necessary to enable those skilled in the art to understand the disclosure. [Figure 1A] 1A-1B illustrate end and side views of a system for deploying a stent with a functional and / or therapeutic agent according to one or more embodiments described herein. [Figure 1B] 1A-1B illustrate end and side views of a system for deploying a stent with a functional and / or therapeutic agent according to one or more embodiments described herein. [Figure 2A] 2A-2D illustrate example aspects of deployment of a stent with functional and / or therapeutic agents according to one or more embodiments described herein. [Figure 2B] 2A-2D illustrate example aspects of deployment of a stent with functional and / or therapeutic agents according to one or more embodiments described herein. [Figure 2C]2A-2D illustrate example aspects of deployment of a stent with functional and / or therapeutic agents according to one or more embodiments described herein. [Figure 2D] 2A-2D illustrate example aspects of deployment of a stent with functional and / or therapeutic agents according to one or more embodiments described herein. [Figure 3A] FIG. 3A is a cross-sectional view of an end-to-end anastomosis formed using a stent with a functional and / or therapeutic agent according to one or more embodiments described herein. [Figure 3B] FIG. 3B is a cross-sectional view of a stent with functional and / or therapeutic agents bridging apposed tissue walls according to one or more embodiments described herein. [Figure 4A] FIG. 4A illustrates an example of a stent according to one or more embodiments described herein deployed in a body lumen. [Figure 4B] 4B-4E illustrate various examples of stents, such as those of FIG. 4A, having functional and / or therapeutic agents deployed thereon, according to one or more embodiments described herein. [Figure 4C] 4B-4E illustrate various examples of stents, such as those of FIG. 4A, having functional and / or therapeutic agents deployed thereon, according to one or more embodiments described herein. [Figure 4D] 4B-4E illustrate various examples of stents, such as those of FIG. 4A, having functional and / or therapeutic agents deployed thereon, according to one or more embodiments described herein. [Figure 4E] 4B-4E illustrate various examples of stents, such as those of FIG. 4A, having functional and / or therapeutic agents deployed thereon, according to one or more embodiments described herein. [Figure 5A] FIG. 5A illustrates the percutaneous infusion of functional and / or therapeutic agents along the surface of a deployed stent according to one or more embodiments described herein. [Figure 5B] FIG. 5B illustrates intraluminal or intraductal infusion of functional and / or therapeutic agents along the surface of a deployed stent according to one or more embodiments described herein. [Figure 6] FIG. 6 is a perspective view of an example of a deployed stent with functional and / or therapeutic agents and retention prongs according to one or more embodiments described herein. [Figure 7] FIG. 7 is a perspective view of one example of a device useful for deploying a stent and / or functional and / or therapeutic agent according to one or more embodiments described herein. [Figure 8A] 8A-8B are top and perspective views of a delivery system end cap according to one or more embodiments described herein. [Figure 8B] 8A-8B are top and perspective views of a delivery system end cap according to one or more embodiments described herein. DETAILED DESCRIPTION OF THE INVENTION

[0016] The following detailed description should be read with reference to the drawings illustrating exemplary embodiments. The present disclosure is not limited to the specific embodiments described, as such embodiments may vary. The terminology used herein is for the purpose of describing specific embodiments only and is not intended to limit the scope of the appended claims. Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure pertains. Finally, while embodiments of the present disclosure may be described with specific reference to medical devices and systems and procedures for treating the gastrointestinal system, it should be understood that such medical devices and methods may be used to treat tissues in the abdominal cavity, digestive system, urinary tract, reproductive tract, respiratory system, cardiovascular system, circulatory system, and the like. Structures and configurations, as well as methods of deployment, to stabilize, maintain, and / or assist fluid flow paths may find utility beyond the treatments discussed herein.

[0017] As used herein, "proximal end" refers to the end of the device closest to the user (such as a medical professional or clinician or technician or operator or physician, such terms are used interchangeably herein without limitation, and include automated controller systems, etc.) when introducing the device into a patient, and "distal end" refers to the end of the device or object furthest from the user along the device during implantation, placement, or delivery.

[0018] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term "or" is generally used in its sense including "and / or" unless the content clearly dictates otherwise.

[0019] As used herein, the conjunction "and" includes each of the structures, components, features, etc. so connected, unless the context clearly dictates otherwise, and the conjunction "or" includes one or the other of the structures, components, features, etc. so connected, alone and in any combination and number, unless the context clearly dictates otherwise.

[0020] All numerical values ​​herein are assumed to be modified by the term "about," whether explicitly stated or not. The term "about" in the context of numerical values ​​generally refers to a range of numbers that one of ordinary skill in the art would consider equivalent to the stated value (e.g., having the same function or result). In many cases, the term "about" can include numbers rounded to the nearest significant figure. Other uses of the term "about" (e.g., in contexts other than numerical values) can be assumed to have their ordinary and customary definition as understood from and consistent with the context of this specification, unless otherwise specified. The recitation of numerical ranges or values ​​by endpoints includes all numbers within that range, including the endpoints (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5), and fractions thereof.

[0021] It should be noted that references herein to "one embodiment," "some embodiments," "other embodiments," etc., indicate that the described embodiment may include one or more particular features, structures, and / or characteristics. However, such a description does not necessarily mean that all embodiments include the particular feature, structure, and / or characteristic. In addition, if a particular feature, structure, and / or characteristic is described in connection with one embodiment, it should be understood that such feature, structure, and / or characteristic may also be used in connection with other embodiments, whether or not explicitly described, unless expressly stated to the contrary.

[0022] It should be noted that the present specification and drawings may refer to examples of stents. The methods and features described herein apply to stents, broadly understood, and are presently contemplated as being applicable to a variety of devices, such as grafts, tissue scaffolds, other medical implants, or self-expanding or expandable structures. It will be understood that reference to a stent herein implicitly includes reference to such suitable devices for brevity, without intending to be limiting.

[0023] Various procedures involve the creation and / or maintenance of a flow path through at least one body lumen and / or across tissue, for example, for fluid flow and / or drainage therethrough. Medical devices such as stents, grafts, etc., can be used to hold the flow path open. In many procedures, stents, grafts, or other medical devices for maintaining an open flow path can be implanted endoscopically. Various additional or alternative procedures involve the use of stents, grafts, or other medical devices to hold portions of body tissue (e.g., to heal a lesion) or hold body tissues in apposition. Such procedures can be advantageously performed endoscopically, as endoscopic procedures are less invasive than traditional open or laparoscopic surgery. For example, an endoscope can be introduced into a body lumen without the need for extensive surgical incisions.

[0024] Such procedures have encountered various challenges. The patient's natural movements can impose various forces on the implanted medical device, which can increase the risk of the medical device migrating. Additionally or alternatively, implanting a medical device within the body can elicit an immune response from surrounding tissue. Any of these risks can result in unwanted tissue irritation and / or discomfort for the patient. If the device migrates, fluids can undesirably leak around the device, for example, into other areas of the body, which can cause further discomfort and / or risk to the patient. A subsequent procedure may be required to reposition or retrieve the detached or displaced medical device.

[0025] Thus, there is a need for improved systems for maintaining the position of implanted medical devices and / or preventing, reducing, or managing irritation of tissue surrounding the implant. More generally, there is a need to increase the functionality of implanted devices, such as to enable the application of a greater variety of functionalities and / or therapeutic agents to the device deployment site. It will be understood that terms such as applying, deploying, delivering, providing functionality and / or therapeutic agents (and their conjugations and other grammatical forms) may be used interchangeably herein without any intended limitation, unless otherwise indicated.

[0026] With the above considerations in mind, various beneficial medical results can be achieved by the following disclosed devices and / or methods. For example, stents can be deployed within or across body tissues or lumens with at least one functional and / or therapeutic agent selected to treat tissue at the deployment site. In some embodiments, the agent provides a mechanical effect, such as aiding or promoting adhesion of tissue to other tissues (e.g., to close a lesion, form an anastomosis, or hold tissues in apposition) or to the stent (e.g., to hold the stent in place relative to the deployment site to resist migration). In some embodiments, the agent provides a biological cell therapy effect, such as hemostasis, promoting healing, helping to irritate and / or manage inflammation in surrounding tissues, reducing discomfort, and / or reducing infection (e.g., including antimicrobial agents). Examples of agents with adhesive properties that can be used with the devices, systems, and methods of the present disclosure include, but are not limited to, cyanoacrylates, LED-cured adhesives, hydrogels, and the like. Examples of agents with healing properties (e.g., tissue healing agents) include, but are not limited to, silk hydrogels, chitin hydrogels, growth factor gels, anti-inflammatory agents, antibacterial and other antimicrobial agents (including, but not limited to, agents with biocidal and biostatic properties), antibiotics, hemostatic agents, sclerosing agents, discomfort reducers (including, but not limited to, antispasmodics, ketorolac, corticosteroids, narcotic analgesics, non-narcotic analgesics, local anesthetics, alpha-adrenergic blockers, and combinations thereof), growth inhibitors, growth promoters, etc. Examples of agents with therapeutic and / or protective properties include, but are not limited to, bioabsorbable gels as carriers for chemotherapeutic agents, imaging agents, and / or therapeutic agents, growth factor inhibitors, anti-cancer agents (including, for example, agents such as alkylating agents, antimetabolites, antimitotic agents, hormones, immunosuppressants, etc.), etc. Functional and / or therapeutic agents can be provided in any desired form suitable for the intended purpose, such as a suspension, bound to a polymer, incorporated into a coating, etc.Any suitable delivery agent or carrier, such as a hydrogel (e.g., polyvinyl alcohol (PVA), sodium alginate (SA), carboxymethylcellulose (CMC), hyaluronic acid (HA), hydroxypropyl methylcellulose, hydroxyethyl starch (HES), xanthan gum (XG), gellan gum, gelatin, agar, polylactic acid (PLA), chitosan, lecithin), can be used for such agents. The functional and / or therapeutic agent can be at any desired weight per volume of delivery agent or carrier as indicated to achieve the desired functional and / or therapeutic effect. For example, the functional and / or therapeutic agent can be suspended or formulated in the delivery agent or carrier at a desired weight per volume of delivery agent or carrier. The drug / gel injection force, excluding the force of stent deployment, is preferably less than 60 N. The viscosity at the desired shear rate should preferably be less than 60 N without resulting in an injection force exceeding clinically acceptable levels for the procedure. Additionally, the delivery agent or carrier may be formulated to respond to the environment in which it is placed, for example, by absorbing water and swelling, or by releasing water and shrinking, or by affecting the release of functional and / or therapeutic agents therefrom. The agents listed above may be any known or previously known agents in the art, and it will be understood that the broad principles of the present disclosure are not limited by the specific examples. The embodiments are not limited in this context. The methods and systems described herein can provide for the deployment of a stent and one or more functional and / or therapeutic agents together or in separate steps. Percutaneous and intraluminal deployment methods are currently contemplated.

[0027] The present disclosure provides devices, systems, and methods for providing functional and / or therapeutic agents in association with devices or structures, such as stents. For convenience, and without intending to be limiting, reference will be made to stents, but such reference is intended to encompass other devices and / or structures suitable for use in accordance with the various principles of the present disclosure, for example, any structure that may form or provide a scaffold for functional and / or therapeutic agents applied to and maintained at tissue at a treatment site for delivery and / or application thereto.

[0028] Agents such as adhesives, healing agents, and / or therapeutic / protective agents may be delivered with or to a stent in accordance with various principles of the present disclosure. Functional and / or therapeutic agents may be applied to the surface of the stent when the stent is deployed. Additionally or alternatively, a stent may carry or be provided with functional and / or therapeutic agent components that may be inactive until activated, such as at the deployment site (such terms and other similar terms are used interchangeably herein without any limitation). Separate components of functional and / or therapeutic agents may be applied to the surface of such a stent upon deployment of the stent such that the agent components can interact or be activated in situ at the deployment site (or immediately prior to deployment, such as during the deployment procedure, during delivery of the stent). Additionally or alternatively, a stent may be configured to receive or accept functional and / or therapeutic agents after the stent is deployed, preferably to retain such agents relative to the tissue along which the stent is deployed to achieve a desired functional and / or therapeutic effect on the tissue. In some embodiments, a gel as a carrier for the active agent may be formed in situ. For example, one component may be a polymer for the gel and the other component may be a crosslinker that instantly forms a gel when the two components are combined, or the gel may be thermosensitive and form a gel when exposed to body temperature (e.g., tissue at body temperature).

[0029] One particular advantage of the various principles of the present disclosure is the ability to deliver functional and / or therapeutic agents that are not activated until deployment. For example, various conditions at the deployment site (e.g., contact with body tissue at the deployment site, contact with the material of the stent, exposure to body fluids at the deployment site, exposure to body temperature, etc.) may cause activation of functional and / or therapeutic agents that may be delivered in an inactivated state. Another advantage is the ability to customize a given stent to a patient's treatment needs by selecting one or more of a variety of agents to be used in conjunction with a stent that does not initially carry, convey, or have associated therewith a particular agent, thereby expanding the potential uses of a given stent.

[0030] In accordance with various principles of the present disclosure, a stent is configured to provide a region for retaining a functional and / or therapeutic agent against or adjacent to the tissue to be treated. For example, when in a deployed configuration, the stent may have a longitudinal extent defining a first retention member along a first end, a second retention member along a second end, and an intermediate region between the first and second retention members. The first retention member has a first diameter, the second retention member has a second diameter, and the intermediate region has an intermediate diameter smaller than both the first and second diameters. Thus, a functional and / or therapeutic agent may be retained or contained between the first and second retention members and along the intermediate region. For example, a functional and / or therapeutic agent may be provided, deployed, or deposited (such terms and similar terms are used interchangeably herein without limitation) to provide a desired effect on the tissue and retained within a volume extending around the intermediate region, between the retention members, and between the stent and the tissue in which the stent is placed.

[0031] The various principles of the present disclosure may be applied to any of a variety of stent configurations. For example, the principles of the present disclosure may be applied to stents configured to drain an anatomical region, to open, create, maintain, or treat a flow path, to hold apposed tissues together (such as to close a wound or lesion or form an anastomosis), or for other therapeutic purposes. In some embodiments, the stent may simply provide a structure or scaffolding for functionality and / or therapeutic agents. The principles of the present disclosure may be applied to extend, improve, or enhance the use of stents in conjunction with full-thickness resection of tissue by using the stent to close the resected tissue.

[0032] A delivery and deployment system for delivering and deploying a stent and associated functional and / or therapeutic agents may include a handle with a first control knob for a first sheath disposed over the stent, a second control knob for a second sheath disposed over the first sheath, and a third control knob for an inner member on which the stent is deployed, each control knob being capable of movement independent of the other control knobs. The first port may be provided for accessing a guide lumen or channel through the inner member, such as for delivery of a guidewire (e.g., to assist in navigation to a desired deployment site) or a needle or injectable material (e.g., imaging material, fluoroscopy agent, etc., contrast agent). The second port may be provided for delivery of functional and / or therapeutic agents to the stent, including, but not limited to, at the deployment site before the stent is delivered, on the stent as it is being deployed, on an already deployed stent, and / or adjacent to an already deployed stent.

[0033] The detailed description should be read with reference to the drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention. Referring now to the drawings, as shown in FIGS. 1A-1B, various systems according to the present disclosure, including a deployment system 100, may include a stent 110 disposed between an inner member 102 and a first sheath 104 of the deployment system 100. The stent 110 may be configured to shift between a first configuration (e.g., a collapsed configuration, a constrained configuration, an elongated configuration, a delivery configuration, etc.) and a second configuration (e.g., an expanded configuration, an unconstrained configuration, a deployed configuration, etc.). For brevity, and without any limitation, a first configuration as described herein may additionally or alternatively be understood to refer to a constrained configuration, an elongated configuration, a delivery configuration, etc., and a second configuration as described herein may additionally or alternatively be understood to refer to an unconstrained configuration, an expanded configuration, a deployed configuration, etc. Although stent 110 is shown in a first configuration in FIGS. 1A-1B, it may have a second configuration having one or more similarities to the second configuration of stent 210 shown in FIGS. 2B-2D.

[0034] The stent 110 may be solid, woven, braided, or of other recognizable form and may be made from metal, polymer, silicone, or other materials. In various embodiments, the stent 110 may be formed from a shape-memory material. For example, the stent 110 may be formed from one or more shape-memory wires, such as alloys such as Nitinol, Platinol, and the like. The stent 110 may be pre-set to a second configuration and then constrained within the first sheath 104. Various known or previously known coverings (not shown for simplicity), such as polymers, elastomers, silicones, or lubricious coatings, may be applied to selected regions of the stent 110. It will be understood that terms such as covering, coating, and sheath may be used interchangeably herein without any limitation. The provision of a covering may contribute to the mechanics of the stent 110, impart structural stability, occlude (partially or completely) the flow of material through the wall of the stent 110, and / or inhibit tissue ingrowth. Selected regions of the stent 110 may be left uncoated to allow tissue ingrowth that resists migration of the stent 110, and optionally coated regions resist folding and migration, thus facilitating sufficient immobility to allow ingrowth into the uncoated regions.

[0035] Stent 110 can be disposed between first sheath 104 and inner member 102 such that stent 110 is held in a first configuration. First interstitial spaces 103 and / or second interstitial spaces 105 can exist between stent 110 and inner member 102 or first sheath 104, respectively. It will be understood that first interstitial spaces 103 and / or second interstitial spaces 105 are optional and need not be large enough to allow stent 110 to fit loosely within first sheath 104. In various embodiments, inner member 102 and first sheath 104 can securely hold stent 110 therebetween.

[0036] The second sheath 106 may be disposed around the first sheath 104. The functional and / or therapeutic agent 150 may be disposed in the space 107 between the first sheath 104 and the second sheath 106. The functional and / or therapeutic agent 150 may be in the form of a solid sheath, a semi-solid sheath, or a fluid (e.g., a gel or liquid). In either case, particularly in examples in which the functional and / or therapeutic agent 150 comprises a fluid, a cap 180 such as that shown in FIG. 8 (and described in further detail below) may be provided along the distal end 100d of the deployment system 100, such as by being fitted over at least the distal end 104d of the first sheath 104 and / or the distal end 106d of the second sheath 106, prior to the procedure and / or until the practitioner is ready to release the functional and / or therapeutic agent 150. Alternatively or additionally, a membrane may be provided along the distal end 100d of the deployment system 100, the membrane being sufficiently thin or configured to be pierceable by a stylet passing through the space 107, ruptured by the pressure of the agent, or dissolvable (e.g., at body temperature).

[0037] In various embodiments, the functional and / or therapeutic agent 150 may have adhesive and / or healing and / or other therapeutic (e.g., tissue treatment) properties. For example, the functional and / or therapeutic agent 150 may include one or more of adhesives or sealants or other agents with adhesive properties (e.g., cyanoacrylates, LED-cured adhesives, hydrogels, etc.), various healing hydrogels / gels (e.g., silk hydrogels, chitin hydrogels, growth factor gels) and / or other healing agents (anti-inflammatory agents), growth factors and / or inhibitors, therapeutic and / or protective agents (e.g., chemotherapeutic and / or radiotherapeutic agents), or the like as described above. The embodiments are not limited in this context.

[0038] In some embodiments, the cutting element 108 may be disposed at or on the distal end 102d of the inner member 102. For example, the cutting element 108 may comprise an electrocautery tip, a blade, a sharpened needle tip, or the like, which may be configured to puncture or cut tissue. The cutting element 108 may be used to create a pathway through tissue through which the stent 110 can extend. In some embodiments, a lumen or channel is formed through the inner member 102, and a guidewire may be passed therethrough and used to guide the stent 110, inner member 102, first sheath 104, and second sheath 106 to the deployment site. Additionally or alternatively, such a lumen or channel may be used to deliver a needle, an injectable agent, or the like therethrough.

[0039] In various embodiments, one or both of first sheath 104 and second sheath 106 may be distally longitudinally extendable (toward the distal end 100d of deployment system 100) and / or proximally longitudinally retractable (toward the proximal end 100p of deployment system 100) relative to inner member 102 and / or relative to each other. Inner member 102 may be distally longitudinally extendable and / or proximally longitudinally retractable relative to first sheath 104 and / or second sheath 106. In various embodiments, distal longitudinal extension of the inner member 102 relative to the first sheath 104 and / or proximal longitudinal retraction of the first sheath 104 relative to the inner member 102 may enable the stent 110 to transition from its first configuration (when within the first sheath 104) to its second configuration upon exiting or being withdrawn from the first sheath 104.

[0040] Additionally or alternatively, when the second sheath 106 is retracted proximally with or relative to the first sheath 104, the functional and / or therapeutic agent 150 may be withdrawn from the second sheath 106 and / or moved distally relative to the distal end 106d of the second sheath 106 and / or moved distally relative to the distal end 104d of the first sheath 104. Alternatively or additionally, the functional and / or therapeutic agent 150 may be pushed or extended distally from between the first sheath 104 and the second sheath 106. For example, the functional and / or therapeutic agent 150 may be moved distally relative to the distal ends 104d, 106d of the first and second sheaths 104, 106 as a result of pressure applied thereto from a proximally disposed pushing member (not shown), or a proximal source of air pressure, or other force that may be controlled via a control handle 1000 coupled to the proximal end 100p of the deployment system 100 (such as the proximal end of one or more of the inner member 102, the first sheath 104, or the second sheath 106). For example, the control handle 1000 as shown in FIG. 7 (and described in further detail below) may include means for affecting pressurization of air proximal to the functional and / or therapeutic agent 150 (e.g., into the space 107), thereby resulting in distal displacement of the functional and / or therapeutic agent 150.

[0041] Various aspects of an example deployment of an example embodiment of stent 210 are shown in FIGS. 2A-2D. While stent 210 is illustrated as being formed from braided wire, various alternative known and previously known structures and / or configurations of stents are within the scope and spirit of the present disclosure. Notably, stent 210 can shift or transition between a first configuration and a second configuration, as described with respect to stent 110, and can be similarly disposed between inner member 102 and first sheath 104, as described with respect to FIGS. 1A-1B, with inner member 102 extending through lumen 211 extending longitudinally through stent 210. In some embodiments, a cover can be provided over stent 210, as described with respect to stent 110.

[0042] 2A has a first end 212, a second end 214, and an intermediate segment 216 extending therebetween, which may have the same or substantially the same diameter D1 in a first configuration. As seen in FIGS. 2A-2B, when first sheath 104 and second sheath 106 are retracted proximally relative to inner member 102 and stent 210 in the proximal direction of arrow A, and / or when inner member 102 (carrying stent 210) is extended distally relative to first sheath 104 or both first sheath 104 and second sheath 106 in the distal direction of arrow B, first end 212 of stent 210 can transition to a second configuration of stent 210, which may define a first retention member 220 along first end 212 of stent 210. In some examples, diameter D2 of first retention member 220 (of a portion of stent 210 in the second configuration) is larger than diameter D1 of first end 212 of stent 210 in the first configuration. In various embodiments, first retention member 220 may be a double-walled retention member, in some examples having a first retention member inner wall 222 facing intermediate segment 216 (e.g., proximally facing) and a first retention member outer wall 224 facing away from intermediate segment 216 (e.g., distally facing), generally coupled to first retention member inner wall 222, one or both of which may be configured to contact tissue.

[0043] The first sheath 104 and the second sheath 106 may be further retracted proximally in the proximal direction of arrow A relative to the inner member 102, and / or the inner member 102 may be extended distally in the distal direction of arrow B relative to the first sheath 104 or both the first sheath 104 and the second sheath 106, such that the intermediate segment 216 forms a saddle region 230 extending proximally from the first retention member 220 in the second configuration. The saddle region 230 may be generally cylindrical. The saddle region 230 may have the same or a different diameter (e.g., diameter D3) as the intermediate segment 216 in the first configuration (e.g., diameter D1). In some examples, the saddle region 230 may have a larger diameter than the intermediate segment 216 in the first configuration.

[0044] 2C , first sheath 104 and second sheath 106 may be retracted even further proximally in the proximal direction of arrow A relative to inner member 102, or inner member 102 may be extended distally in the distal direction of arrow B relative to first sheath 104, or both first sheath 104 and second sheath 106, such that second end 214 forms second retention member 240 proximally adjacent saddle region 230. In some examples, diameter D4 of second retention member 240 (of a portion of stent 210 in the second configuration) may be larger than diameter D1 of second end 214 of stent 210 in the first configuration. In some examples, the second retaining member 240 may be a double-walled retaining member having a second retaining member inner wall 242 (e.g., proximally facing) and a second retaining member outer wall 244 facing away from the intermediate segment 216 (e.g., distally facing), one or both of which may be configured to contact tissue.

[0045] The first retention member 220 and the second retention member 240 may have the same or different shapes, sizes, and / or configurations. For example, the diameters D2 and D4 may be the same or different. In various examples, one or both of the first retention member 220 and / or the second retention member 240 may include a flange, such as a double-walled flange. In other examples, the first retention member 220 and / or the second retention member 240 may include a ridge, bump, flare, ramp, cylindrical portion, or other surface feature (not shown) having a diameter larger than the diameter of the saddle region 230, which may extend completely or partially around the circumference of the stent 210. In some embodiments according to the present disclosure, the diameters D2 and D4 may be larger than the diameter of a cutting element (such as the cutting element 108 illustrated in FIG. 1B, but not shown), such that the first retention member 220 and the second retention member 240 may be wider than the anastomosis formed by the cutting element.

[0046] In some examples, stent 210 may include a first lip 226 that may extend (e.g., extend distally) from first retention member 220 away from saddle region 230. Similarly, stent 210 may include a second lip 246 that may extend from second retention member 240 away from saddle region 230. Diameter D5 of first lip 226 and diameter D6 of second lip 246 may be the same or different diameters and may be the same or different from diameter D3 of saddle region 230. In some embodiments, diameter D5 and / or diameter D6 are larger than diameter D3, such that stent 210 has openings through retention members 220, 240 at its respective ends 212, 214 that are wider than the diameter of the portion of lumen 211 extending through saddle region 230, which may facilitate greater fluid flow through lumen 211 extending through stent 210 when in the second configuration.

[0047] As can be seen with reference to the examples shown in Figures 2A-2C, functional and / or therapeutic agents 150 can be deployed and positioned along stent 210 when stent 110 is deployed. For example, positive pressure applied from the proximal end 100p of the deployment system 100 into the space 107 between the first sheath 104 and the second sheath 106, as actuated by the handle 1000 (shown in FIG. 7 ), may optionally be exerted on the functional and / or therapeutic agent 150 in coordination with proximal retraction of the first sheath 104 and the second sheath 106 relative to the inner member 102 and / or in coordination with distal extension of the inner member 102 relative to the first sheath 104 and the second sheath 106, such that when the stent 210 is released distally from within or withdrawn from the first sheath 104, the functional and / or therapeutic agent 150 is disposed along a portion of the stent 210 (e.g., along one or more of the first end 212, the intermediate segment 216, or the second end 214). In some examples, as shown in Figures 2A-2C, a layer of functional and / or therapeutic agent 150 may therefore be deposited along a portion of the outer surface of stent 210, or along the entire outer surface (e.g., as shown in Figure 3A or 3B).

[0048] In another example, positive pressure applied from the proximal end 100p of the deployment system 100 into the space 107 between the first sheath 104 and the second sheath 106 may be provided via the handle 1000 (shown in FIG. 7 ) to selectively and / or partially position the functional and / or therapeutic agent 150 along the stent 210. For example, the functional and / or therapeutic agent 150 may be positioned such that all or part of one or more of the lip 226, the first retention member outer wall 224, the first retention member 220, the first retention member inner wall 222, the saddle region 230, the second retention member inner wall 242, the second retention member 240, the second retention member outer wall 244, or the lip 246 are not covered with a layer of the functional and / or therapeutic agent 150 once deployed. In other words, the functional and / or therapeutic agent 150 may intermittently, discontinuously, or partially cover the stent 210. For example, the stent 210 as shown in FIG. 3B includes functional and / or therapeutic agents 150 disposed only along the saddle region 230. In other embodiments, not shown for simplicity (though such concepts will be readily understood by those skilled in the art), the functional and / or therapeutic agent 150 may be disposed not along the saddle region 230 but along each of the first and second retention members 220, 240, along only the saddle region 230 and the inner wall 222 of the first retention member and the inner wall 242 of the second retention member, along the lip 226 and the first retention member 220, along the lip 246 and the second retention member 240, or along any other combination of the lip 226, the outer wall 224 of the first retention member, the first retention member 220, the inner wall 222 of the first retention member, the saddle region 230, the inner wall 242 of the second retention member, the second retention member 240, the outer wall 244 of the second retention member, or the lip 246.

[0049] It will be appreciated that if the stent 210 includes a covering (not shown for simplicity of the drawings), the covering may help prevent the functional and / or therapeutic agent 150 from flowing through one or more holes (e.g., interstices in the braid) in the porous surface of the stent 210 and into the lumen 211. Thus, the covering may help maintain the location of the functional and / or therapeutic agent 150 along the surface of the stent 110. The stent 210 may include a complete or partial covering. For example, a partial covering may include one or more segments of covering along its length in areas where the presence of the functional and / or therapeutic agent 150 is desired, while the remainder of the stent 210 may be free of covering (thus, for example, allowing the functional and / or therapeutic agent 150 to flow or be evacuated through the porous surface of the stent 210, or the functional and / or therapeutic agent 150 not being provided along such portions of the stent 110). In some embodiments, one or more markers along the stent 210 can indicate the beginning or end of a partial coverage (not shown) or other region along the stent 210 to indicate where the functional and / or therapeutic agent 150 should be placed. Thus, overuse of the functional and / or therapeutic agent 150 can be minimized, which can reduce the amount of functional and / or therapeutic agent 150 required for initial loading between the first sheath 104 and the second sheath 106 and / or minimize the amount of functional and / or therapeutic agent 150 that enters the patient's body. In some embodiments, the functional and / or therapeutic agent 150 can be placed before and / or after placement and deployment of the stent 210 to act as a buffer (e.g., for areas of the lesion that may be longer than the stent 210).

[0050] Although functional and / or therapeutic agent 150 may be disposed along one or more portions of stent 210 such that the respective diameters along stent 210 are greater than diameter D1, diameter D2, diameter D3, diameter D4, diameter D5, or diameter D6, in various embodiments, functional and / or therapeutic agent 150 may be disposed along stent 210 such that the respective diameters of stent 210 do not substantially increase. The embodiments are not limited in this context.

[0051] The functional and / or therapeutic agent 150 may, in some embodiments, include a curing agent, such as an adhesive, that may automatically harden over time, such as upon exposure to living tissue or body heat, or upon an external stimulus. For example, the functional and / or therapeutic agent 150 may harden upon exposure to UV light, such as from a light extending through a working channel of the control handle 1000 as illustrated in FIG. 7.

[0052] In some embodiments, the functional and / or therapeutic agent 150 may include multiple components that, upon contact with each other, result in a hardening and / or polymerization process. For example, the functional and / or therapeutic agent 150 may include a fibrin glue, where a first component may include thrombin and a second component may include fibrinogen. In some examples where the functional and / or therapeutic agent 150 includes multiple components that may be particularly reactive with each other, the first functional and / or therapeutic agent component 152 may be disposed (e.g., in an inactive state) in the space 107 between the first sheath 104 and the second sheath 106, and the second functional and / or therapeutic agent component 154 may be disposed along the surface of the stent 210 prior to deployment.

[0053] As shown in Figure 2D, rather than a fully active form of functional and / or therapeutic agent 150 (as described with respect to Figures 2A-2C), an example of a first functional and / or therapeutic agent component 152 is shown disposed within the space 107 between the first sheath 104 and the second sheath 106, and may be disposed (e.g., deposited) along the stent 210 similar to the functional and / or therapeutic agent 150 along the stent 210 as described above with respect to Figures 2A-2C. However, unlike the example shown in Figures 2A-2C, the stent 210 has a second functional and / or therapeutic agent component 154 along all or a portion thereof (first end 212, second end 214, and / or intermediate segment 216) prior to deployment. Thus, once the first functional and / or therapeutic agent component 152 is deposited on the stent 210, the first functional and / or therapeutic agent component 152 may be deposited onto the second functional and / or therapeutic agent component 154 already in place on the stent 110, and the first functional and / or therapeutic agent component 152 and the second functional and / or therapeutic agent component 154 may react with one another such that they polymerize in situ. The embodiments are not limited in this context.

[0054] Although not shown in Figures 2A-2D for simplicity, stent 210 can be deployed across one or more tissues, body lumens, etc. to form a flow path therebetween and / or join tissues. For example, as shown in Figure 3A, an example embodiment of stent 210 as shown in the example of Figures 2A-2D can be used to form an end-to-end anastomosis. As shown in Figure 3B, an example embodiment of stent 210 as shown in the example of Figures 2A-2D can also be used to form a side-to-side anastomosis.

[0055] As shown in FIG. 3A, the stent 210 can be deployed from a deployment system 100 (as described with respect to FIGS. 2A-2D) to extend across and through body lumens L1 and L2 defined by tissues T1 and T2, respectively. For example, tissues T1 and T2 can be blood vessels, portions of the intestine, or other tissues. In some embodiments, deployment of the first retention member 220, as described above, can be within body lumen L2. For example, the deployment system 100 can be introduced through body lumen L1 and extended to or into body lumen L2 (not shown). In this example, the first sheath 104 and the second sheath 106 can be retracted proximally relative to the inner member 102 while all three are positioned within body lumen L2, and / or the inner member 102 can be extended distally relative to the first sheath 104 and the second sheath 106 into body lumen L2. In either case, first end 212 may transition into first retention member 220 within body lumen L2 so that, among other things, first retention member 220 engages the inner surface of tissue T2, thereby anchoring, securing, anchoring, or retaining the position of first end 212 of stent 210 within body lumen L2. Deployment system 100 may be retracted proximally (with first end 212), for example, in the direction of arrow A, such that tissue T2, along with deployment system 100 and stent 210, is moved into apposition with tissue T1. Second retention member 240 is then deployed within body lumen L1, for example, via the steps described above, so that second retention member 240 contacts tissue T1 and is anchored, anchored, or retained within body lumen L1. The functional and / or therapeutic agent 150 may often act to increase the holding strength of the anastomosis facilitated by the stent 210 by adhering to one or both of the tissues T1 or T2 and / or by adhering the tissues T1 and T2 to one another (such as in instances where the tissues T1 and T2 form an end-to-end anastomosis).

[0056] In the example shown in FIG. 3B , a stent 210 can be used to facilitate drainage from one organ or body lumen to another. For example, a cutting element 108 (as illustrated in FIG. 1B ) can be advanced distally from body lumen L3 in the direction of arrow B, through tissue T3, through tissue T4, and into body lumen L4. A first retention member 220 can then be deployed within body lumen L4 according to one or more aspects described above. In some examples, the deployment system 100 (together with the first retention member 220) is advanced distally such that tissue T4 is apposed to tissue T3. A second retention member 240 is then deployed within body lumen L3, e.g., via the steps described above, such that the second retention member 240 contacts tissue T3 and is secured, anchored, or retained within body lumen L3. In some embodiments, functional and / or therapeutic agent 150 can adhere to one or both of tissue T3 or tissue T4 to hold tissue T3 and tissue T4 in apposition with each other and with stent 110. For example, saddle region 230 can extend across tissue T3 and tissue T4, and functional and / or therapeutic agent 150 along saddle region 230 can adhere to both tissue T3 and tissue T4.

[0057] It will be appreciated that the principles of the present disclosure regarding the delivery and deployment of functional and / or therapeutic agents 150 need not be limited to anastomoses. For example, as shown in FIGS. 4A-4E, a stent 310 may be placed within a body lumen L5, such as an intact or single body lumen L5, to deliver or provide functional and / or therapeutic agents 150 to tissue. For example, an occlusion within the lumen may be opened by the stent 510, and / or functional and / or therapeutic agents 150 may be delivered along the lumen to an affected area (e.g., diseased, injured, etc.). The stent 310 may share one or more features or aspects of the stents 110 and 210 described above. For example, the stent 310 may be provided with a cover (e.g., a silicone cover or coating) thereon. The stent 310 may have a first end 312 along which a first retention member 320 may be formed or provided, a second end 314 along which a second retention member 340 may be formed or provided, and an intermediate segment 316 along which a saddle region 330 extends. A functional and / or therapeutic agent 150 may be associated with the stent 310. In some embodiments, the functional and / or therapeutic agent 150 is provided longitudinally along the saddle region 330 between the first retention member 320 and the second retention member 340, and the stent 310 is positioned with the functional and / or therapeutic agent 150 disposed along the tissue T5 having the area to be treated. The functional and / or therapeutic agent 150 may be associated with the stent 310 in any of a variety of ways, as described above. For example, the functional and / or therapeutic agent 150 may be disposed on the stent 310 when the stent 310 is deployed and / or may be provided in the form of one or more functional and / or therapeutic agent components, at least one of which is provided on the stent 310 prior to deployment, such as before delivery, and at least another of which is provided on the stent 310 during deployment to cause activation of the functional and / or therapeutic agent 150 at the deployment site. Additionally or alternatively, the functional and / or therapeutic agent 150 may be provided after the stent 310 is deployed.Stent 310 may be configured to carry additional or alternative functional and / or therapeutic agents 150 along its saddle region 330. For example, first retention member 320 and second retention member 340 may hold tissue T5 spaced from saddle region 330 to create a working space into which functional and / or therapeutic agents 150 may be infused after deployment of stent 310, for example, according to methods described below.

[0058] The functional and / or therapeutic agent 150 may be provided in increasing and / or predetermined volumes along the saddle region 330 of the stent 310, such that the volume 313 defined by the saddle region 330, the first retention member 320, the second retention member 340, and the tissue T5 (the tissue forming the wall of the lumen L5 in which the stent 310 is disposed) can be filled with the functional and / or therapeutic agent 150 at varying rates, as shown in FIG. 4A. For example, FIGS. 4B and 4C each show a larger volume of the functional and / or therapeutic agent 150 being infused along the saddle region 330 between the first retention member 320 and the second retention member 340. FIG. 4D shows an example in which substantially all of the volume 313 defined by the saddle region 330, the first retention member 320, the second retention member 340, and the tissue T5 has been filled with the functional and / or therapeutic agent 150. FIG. 4E shows a cross-sectional view of the example shown in FIG. 4D, illustrating that the lumen 311 of the stent 310 can be maintained through the stent 310, for example, by the effectiveness of a covering over the stent 310 that retains the functional and / or therapeutic agent 150 within the volume 313 and inhibits the flow of the functional and / or therapeutic agent 150 through the wall of the stent 310 into the lumen 311. It will be understood that FIGS. 4A-4E can be viewed as sequentially illustrating different stages of delivery of the functional and / or therapeutic agent 150, or that each of FIGS. 4A-4E can be viewed as illustrating a stent 310 with a different amount of functional and / or therapeutic agent 150 already delivered. In any or all of the example embodiments shown in FIGS. 4A-4E, the functional and / or therapeutic agent 150 can be any desired weight per volume of delivery agent or carrier as shown to achieve the desired functional and / or therapeutic effect at the appropriate viscosity value. For example, the functional and / or therapeutic agent 150 may be suspended or formulated in a delivery agent or carrier at a desired weight per volume of delivery agent or carrier.

[0059] In some embodiments, stent 310 may be disposed within lumen L5 having a tissue region to be treated. Saddle region 330 of stent 310 may be disposed along tissue T5, with the tissue region to be treated being longitudinally disposed between first retention member 320 and second retention member 340. Functional and / or therapeutic agent 150 may be provided in gel or liquid form and contained within volume 313 and retained adjacent to the tissue region to be treated. For example, a cover over stent 310 (as described above) may retain functional and / or therapeutic agent 150 within volume 313 without allowing functional and / or therapeutic agent 150 to leach out of volume 313. In some embodiments, functional and / or therapeutic agent 150 disposed within volume 313 may include agents such as those described above. For example, functional and / or therapeutic agent 150 may include one or more healing agents, such as growth factors, anti-inflammatory agents, etc., that may aid in the healing of tissue T5. In some embodiments, functional and / or therapeutic agent 150 may comprise a first functional and / or therapeutic agent component 152 and a second functional and / or therapeutic agent component 154 that are delivered separately to the deployment site. For example, second functional and / or therapeutic agent component 154 may be delivered with stent 310, or first functional and / or therapeutic agent component 152 may be delivered separately from stent 310 and deployed with stent 310 to contact second functional and / or therapeutic agent component 154. In some embodiments, additional amounts of functional and / or therapeutic agent 150, or first functional and / or therapeutic agent component 152 and second functional and / or therapeutic agent component 154, may be deployed within volume 313 after stent 310 is deployed within lumen L5 (as described in further detail below). Functional and / or therapeutic agent 150 may include at least one additional adhesive component.For example, after deployment of the stent 310, a medical professional may determine that further adhesion of the stent 310 to the surrounding tissue may be desirable, in which case, as described in more detail below, a functional and / or therapeutic agent 150 may be provided after the stent 310 has already been deployed. The embodiments are not limited in this context.

[0060] If the functional and / or therapeutic agent 150, or first and second functional and / or therapeutic agent components 152 and 154, are not deployed with or when the stent 310 is deployed, as described above, a stent configured as stent 310 (e.g., with retention members along each end and a saddle region therebetween) can allow for subsequent deployment of the functional and / or therapeutic agent, or one or more components of the functional and / or therapeutic agent, to a stent such as stent 310 in lumen L5 and the lumen in which the stent is disposed, as shown in Figures 5A and 5B. In some embodiments, the functional and / or therapeutic agent, or one or more components of the functional and / or therapeutic agent, can be injected into a volume 313 defined by the saddle region 330, the first retention member 320, the second retention member 340, and tissue T5. As shown in FIG. 5A , a fluid delivery device 160, such as a syringe or hypodermic needle, can be used to percutaneously deliver a functional and / or therapeutic agent 150 through the wall of lumen L5 into volume 313 between stent 310 and lumen L5. Fluid delivery device 160 may be of any desired shape or configuration and may have a length necessary to percutaneously reach a treatment site in lumen L5, as would be readily understood by one skilled in the art. For example, a functional and / or therapeutic agent may be administered at proximal dosage controller 162 and injected through tissue T5 into volume 313 via tissue-penetrating tip 164. Additionally or alternatively, in some embodiments, the functional and / or therapeutic agent, or one or more components of a functional and / or therapeutic agent, may be injected into volume 313 through the wall of stent 310, as shown in FIG. 5B . For example, fluid delivery device 160 may be delivered transluminally through lumen L5 to a deployment site of stent 310.In some embodiments, a wall of the stent 310 (such as a wall of one of the retention members 320, 340) may be penetrable by the tissue-piercing tip 164 of the fluid delivery device 160, through which a desired amount of functional and / or therapeutic agent may be administered (e.g., from the proximal end of the fluid delivery device 160, such as along the control handle 12 of the delivery and deployment device 10 as shown in FIG. 7 ). As described above, a cover may be provided over the stent 310 and may retain the functional and / or therapeutic agent within the volume 313. Such a cover may be penetrable by the tissue-piercing tip 164 of the fluid delivery device 160 and may self-seal upon withdrawal of the tissue-piercing tip 164 to retain the functional and / or therapeutic agent within the volume 313.

[0061] In some embodiments, as described above, a functional and / or therapeutic agent 150 with an adhesive may be provided within the volume 313 defined between the stent 310 and the lumen L5 to prevent migration of the stent 310 relative to the tissue T5. In some embodiments, it may be desirable to provide a mechanical retention or anti-migration feature instead of, or in addition to, a material- or chemical-based retention agent (such as an adhesive). For example, the functional and / or therapeutic agent 150 may not include an adhesive, and / or an additional retention mechanism may be necessary if forces at the deployment site are deemed to sometimes overcome the adhesive properties of the functional and / or therapeutic agent 150 and / or the retention force exerted by the stent's retention flanges. It will be understood that a stent such as that configured in any or all of FIGS. 4A-4E, 5A, and 5B may be covered or coated to prevent leaching or leakage of the functional and / or therapeutic agent 150 deployed within the volume defined by the inner walls of the retention members and the outer surfaces of their saddle regions. Such a covering generally resists tissue ingrowth and, therefore, may not inhibit stent migration. In accordance with various principles of the present disclosure in some embodiments, as illustrated in FIG. 6 , embodiments of the stent 410 may be provided with additional mechanical fixation elements. The fixation elements may be in the form of one or more anchors 470 along the stent 410, such as along the first end 412 and / or second end 414 of the stent 410. The anchors 470 may be in any desired form, such as loop-shaped projections or fins (as shown), or posts, quills, spikes, barbs, hooks, etc., as known or previously known in the art to facilitate fixation of a device, such as a stent, to tissue and inhibit / prevent migration of the device relative to the tissue. The anchors 470 may be formed from a resilient biocompatible material, such as a metal or polymer, including a wire similar to that forming the stent 410. The anchors 470 may be used to remove the stent 410, such as by pulling on one or more of the anchors 470.Additionally or alternatively, a removal / retrieval device 480, such as a filament, cord, suture, wire, string, band, or the like, can be provided along or around the anchor 470 and / or the ends 412, 414 of the stent 410 to facilitate removal of the stent 410, if desired, in a manner known or heretofore known in the art. The retrieval device 480 can be configured and arranged relative to the stent 410 (e.g., woven into the wall of the stent 410) so that pulling on the retrieval device 480 clamps or contracts the stent 410, facilitating removal of the stent 410. For example, the retrieval device 480 can be in the form of a suture retrieval loop that passes through both the stent 410 and anchor 470 in a manner that retracts the anchor 470 and collapses the stent 410 when the retrieval device 480 is pulled, allowing the stent 410 to be removed from the deployment site.

[0062] The deployment system 100 can be delivered to the treatment site via an endoscope 1100, such as that shown in FIG. 7 . The endoscope 1100 can be any of several types of endoscopes or related medical devices, typically selected based on the particular anatomical structure desired to be reached, such as a colonoscope, duodenoscope, bronchoscope, gastroscope, or ureteroscope, or similar medical device. The deployment system 100 can be inserted through a port 1102 in the handle 1104 of the endoscope 1000 and a working channel through a flexible elongate shaft 1108. A known or previously known deployable scaffold can be provided at the distal end of the elongate shaft 1108 and can be positioned and subsequently expanded within a body lumen to improve access to and / or visualization of the target tissue / treatment site by the endoscope and / or its tools. The endoscope 1100 can include any of a variety of visualization components, such as an optical cable connected to an external light source (not shown). An imaging device, such as a charge-coupled device (CCD) camera, can be located at the distal end to allow a user to visualize the working area. Various additional ports can be provided along the endoscope handle 1104 for delivery of other tools, application of suction, delivery of fluids (e.g., air, water, saline, functional and / or therapeutic agents, etc.), etc., as known or previously known. The endoscope 1000 may include one or more additional controls, such as knobs, that can operate to cause articulation of one or more components thereof. Articulation may include, for example, proximal retraction, distal extension, rotation about a longitudinal axis, translation along a lateral axis, translation along a transverse axis, or any combination thereof.

[0063] Generally, the delivery and deployment device 10 may include a control handle 1000 to facilitate use of the deployment system 100 to treat tissue according to embodiments described herein. The control handle 1000 may include one or more controls, such as actuators 1002, 1004, 1006, which may be coupled to the inner member 102, the first sheath 104, and the second sheath 106, respectively, and may be operable to cause a desired distal advancement / extension or proximal retraction or other movement (e.g., rotation) or combination of movements of the inner member 102, the first sheath 104, and the second sheath 106. An access port 1007 is disposed along the control handle 1000 to facilitate the introduction of pressure through the deployment system 100, advance a functional and / or therapeutic agent 150 (such as through the space 107 between the first sheath 104 and the second sheath 106), and / or introduce additional functional and / or therapeutic agents or components thereof into a stent formed according to various principles of the present disclosure. Additional ports for introducing pressure, fluid (e.g., for suction), or other agents (e.g., imaging materials such as contrast agents) may also be provided, such as in fluid communication with the lumen through the inner member 102.

[0064] As briefly described above, a cap 180 may be provided along the distal end 100d of the deployment system 100, such as by being fitted to at least the distal end 104d of the first sheath 104 and / or the distal end 106d of the second sheath 106, prior to a procedure and / or until the practitioner is ready to release the functional and / or therapeutic agent 150. An example of an embodiment of a cap 180 according to various embodiments of the present disclosure is shown in FIGS. 8A-8B. The cap 180 may be made of flexible and / or non-flexible materials and may be disposable (e.g., single use) or sterilizable and reusable.

[0065] In various embodiments, cap 180 can be configured to form an interference fit with one or more cavities at the distal end of deployment system 100. For example, ridge 182 can be configured to form an interference fit between inner member 102 and first sheath 104, as described with respect to FIGS. 1A-1B, and / or ridge 184 can be configured to form an interference fit between first sheath 104 and second sheath 106. Although not shown for simplicity of illustration, alternatively configured attachment methods and mechanisms for the cap are contemplated. For example, the cap can extend around the distal end of deployment system 100 (e.g., around the outer diameter of second sheath 106) and / or can fit to one or more aspects of the distal end of deployment system 100 via a threaded fit, luer lock, or the like.

[0066] In various embodiments, cap 180 may be removed from the distal end of deployment system 100 prior to introduction of deployment system 100 into the body. In other embodiments, deployment system 100 may be advanced into the body with cap 180 still coupled to its distal end, and cap 180 may be removed during the procedure, for example, by distal extension of inner member 102 relative to first sheath 104 and / or second sheath 106. Cap 180 may then be removed from the body, for example, via a grasper (not shown). For example, if cap 180 is made of a sufficiently flexible material, cap 180 may be bent to have a smaller diameter than the passage through stent 110 (through which inner member 102 extends) and first sheath 104 and second sheath 106 and be removable therethrough. Alternatively, cap 180 may be bioabsorbable or allowed to pass naturally through the body. Thus, it will be appreciated that while cap 180 may be retained on the end of deployment system 100 until the time of the procedure when placement of functional and / or therapeutic agent 150 is desired, in some instances functional and / or therapeutic agent 150 may be retained within deployment system 100 after removal of cap 180, for example, by applying negative pressure proximal to functional and / or therapeutic agent 150 within working channel 16. The embodiments are not limited in this context.

[0067] The embodiments described herein can have a variety of dimensions suitable for use in a variety of applications. Devices formed according to various principles of the present disclosure can have a length in the folded configuration of at least about 14 mm, or as little as 40 mm, or as little as 60 mm, or as little as about 80 mm, or as little as about 100 mm, or as little as about 150 mm, or even as little as 200 mm, including 1 mm increments therebetween. The diameter of devices formed according to various principles of the present disclosure, when in the folded configuration, can be as little as about 3 mm, or even as little as about 2.5 mm, and as large as about 5 mm, or as large as about 6 mm, or as large as about 10 mm, including 0.5 mm increments therebetween. In the expanded configuration, devices formed according to various principles of the present disclosure may be as short as about 14 mm, or as short as about 10 mm, and may have lengths of about 35 mm, or about 50 mm, or about 60 mm, or about 80 mm, or about 100 mm, or about 120 mm, or about 140 mm, or about 160 mm, or about 180 mm, or even about 200 mm, including 1 mm increments therebetween. The saddle diameter of devices formed according to various principles of the present disclosure, when in the expanded configuration, may be as large as about 20 mm, or about 25 mm, or about 30 mm, or about 35 mm, or about 40 mm, or even about 60 mm, and may be as small as about 10 mm, or about 6 mm, or even about 3 mm, including 0.5 mm increments therebetween. The length of the saddle of a device formed according to various principles of the present disclosure, when in an expanded configuration, may be as long as about 10 mm, or as long as about 15 mm, or as long as about 20 mm, or as long as about 30 mm, or as long as about 35 mm, or as long as about 200 mm, or as short as about 10 mm, or as short as about 5 mm, or as short as about 3 mm, including 1 mm increments therebetween.In the expanded configuration, the retention members of devices formed according to various principles of the present disclosure may have diameters as large as about 21 mm, or as large as about 24 mm, or as large as about 29 mm, or as large as about 35 mm, or as large as about 40 mm, or as large as about 60 mm, and as small as about 16 mm, or as small as about 14 mm, or as small as about 5 mm, and lengths as small as about 6 mm, or as long as about 7 mm, or as long as about 10 mm, including diameters and lengths in 0.5 mm increments therebetween, and may have lengths as short as about 3 mm, or as short as about 2 mm, or as short as about 0.5 mm. Devices formed according to various principles of the present disclosure may have diameters in the expanded configuration that are at least about 1.5 times larger than the corresponding diameter of the device in the collapsed configuration, and may have diameters that are about 3 times, or about 5 times, or about 10 times, or even about 15 times larger. For example, a 6 mm (length) stent may have a saddle diameter of about 2.66 mm in the collapsed configuration and a saddle diameter of about 6 mm in the expanded configuration, with an expansion ratio of about 2.25, a flange diameter of about 2.66 mm in the collapsed configuration and a flange diameter of about 14 mm in the expanded configuration, with an expansion ratio of about 5.26, a 20 mm (length) stent may have a saddle diameter of about 3 mm in the collapsed configuration and a saddle diameter of about 20 mm in the expanded configuration, with an expansion ratio of about 6.66, and a flange diameter of about 3 mm in the collapsed configuration and a flange diameter of about 29 mm in the expanded configuration, with an expansion ratio of about 9.66. In devices with at least one lip along a retention member according to various principles of the present disclosure, the length of the lip may be as short as about 1 mm, or even as short as about 0.5 mm, or as long as about 1.5 mm, or as long as about 2.5 mm, or even as long as about 3 mm. In devices with at least one lip along a retention member according to various principles of the present disclosure, the diameter of the lip may be at least about 1 mm wider, or at least about 0.5 mm wider than the diameter of the saddle.In devices having at least one lip along a retention member according to various principles of the present disclosure, the lip diameter can be as small as about 4 mm, or as small as about 6 mm, or as small as about 11 mm, or as large as about 22 mm, or as large as about 27 mm, including 0.5 mm increments therebetween. For example, for a corresponding saddle diameter of about 10 mm, the lip diameter can be at least about 11 mm and up to about 14 mm; for a corresponding saddle diameter of about 15 mm, the lip diameter can be at least about 16 mm and up to about 19 mm; and for a corresponding saddle diameter of about 20 mm, the lip diameter can be at least about 21 mm and up to about 24 mm, including 0.5 mm increments therebetween. In various embodiments of stents having a lumen therethrough, the lumen diameter can be at least about 3 mm and up to about 60 mm, including 0.5 mm increments therebetween. A device formed according to various principles of the present disclosure may have a substantially constant diameter or a varying diameter along its longitudinal axis. For example, the proximal end of a device formed according to various principles of the present disclosure may have a smaller diameter at the proximal end than at the distal end, or a larger diameter at the end and a smaller diameter along the middle section. Various configurations and arrangements of sections with increasing or decreasing diameters, or with substantially constant diameters, are within the scope and spirit of the present disclosure. The embodiments are not limited in this context.

[0068] All of the devices and / or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the devices and methods of the present disclosure have been described in terms of preferred embodiments, it will be apparent to those skilled in the art that variations can be made in the devices and / or methods, and in the steps or sequence of steps of the methods, described herein without departing from the concept, spirit, and scope of the present disclosure. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope, and concept of the present disclosure as defined by the appended claims.

[0069] The foregoing discussion has broad applicability and is presented for purposes of illustration and explanation, and is not intended to limit the present disclosure to the form or forms disclosed herein. It will be understood that various additions, modifications, and substitutions may be made to the embodiments disclosed herein without departing from the concept, spirit, and scope of the present disclosure. In particular, it will be apparent to those skilled in the art that the principles of the present disclosure may be embodied in other forms, structures, arrangements, proportions, and with other elements, materials, and components without departing from the concept, spirit, or scope or characteristics thereof. For example, various features of the present disclosure are grouped together in one or more aspects, embodiments, or configurations for the purpose of streamlining the disclosure. However, it should be understood that various features of a particular aspect, embodiment, or configuration of the present disclosure may be combined in alternative aspects, embodiments, or configurations. While the present disclosure is presented in terms of embodiments, it should be understood that various individual features of the present subject matter need not all be present to achieve at least some of the desired properties and / or advantages of the present subject matter or such individual features. Those skilled in the art will understand that the present disclosure can be used with many modifications, or modifications of the structure, arrangement, proportions, materials, components, and the like used in implementing the disclosure, that are particularly adapted to particular environments and operating requirements, without departing from the principles or spirit or scope of the disclosure. For example, elements shown as integrally formed may be comprised of multiple pieces, or elements shown as multiple pieces may be integrally formed, operations of elements may be reversed or changed, and sizes or dimensions of elements may be changed. Similarly, although operations or actions or steps are described in a particular order, this should not be construed as requiring such a specific order to achieve desirable results, or that all operations or actions or steps should be performed. Additionally, other implementations are within the scope of the following claims. In some cases, the operations recited in the claims can be performed in a different order and still achieve desirable results.The presently disclosed embodiments are therefore to be considered in all respects as illustrative and not restrictive, and the scope of the claimed subject matter is indicated by the appended claims and is not limited to the foregoing description or to the specific embodiments or configurations described or illustrated herein. In view of the above, individual features of any embodiment may be used and claimed separately or in combination with features of that embodiment or any other embodiment, and the scope of the subject matter is indicated by the appended claims and is not limited to the foregoing description.

[0070] In the foregoing description and in the claims that follow, it will be understood that: As used herein, the terms "at least one," "one or more," and "and / or" are open-ended expressions that are both conjunctive and disjunctive in operation. Terms such as "a," "an," "the," "first," and "second" do not exclude a plurality. For example, the term "a" or "an" entity, as used herein, refers to one or more of that entity. Thus, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein. All directional references (e.g., proximal, distal, upper, lower, upward, downward, left, right, lateral, longitudinal, front, rear, top, bottom, above, below, vertical, horizontal, radial, axial, clockwise, counterclockwise, etc.) are used for identification purposes only to aid the reader's understanding of this disclosure and / or serve to distinguish regions of related elements from one another and do not limit the related elements, particularly with respect to the location, orientation, or use of this disclosure. Connection references (e.g., attached, coupled, connected, and joined) should be interpreted broadly and may include intermediate members between and relative movement between a collection of elements unless otherwise indicated. Thus, connection references do not necessarily suggest that two elements are directly connected and in a fixed relationship to one another. Identification references (e.g., primary, secondary, first, second, third, fourth, etc.) are not intended to imply importance or priority, but are used to distinguish one feature from another.

[0071] The following claims are incorporated by reference into this detailed description, with each claim standing on its own as a separate embodiment of the present disclosure. In the claims, the term "comprises / comprising" does not exclude the presence of other elements or steps. In addition, although individual features may be included in different claims, they may be advantageously combined, and their inclusion in different claims does not imply that a combination of features is not feasible and / or advantageous. In addition, a reference to the singular does not exclude a plurality. Reference signs in the claims are provided merely as a clarifying example and should not be construed as limiting the scope of the claims in any way.

Claims

Claim 1: A stent having a lumen extending longitudinally therethrough and configured to shift between a first configuration and a second configuration; Functional and / or therapeutic agents Equipped with In the second configuration, the stent defines a first retention member, a second retention member, and a saddle region extending therebetween; When the stent is deployed in a body lumen in the second configuration, the first retention member, the second retention member, the saddle region, and a portion of a tissue wall of the body lumen define a volume configured to retain the functional and / or therapeutic agent therein.

2. The system described in claim 1, wherein the functional and / or therapeutic agent is in the form of a gel or liquid or in a gel or liquid carrier.

3. The system described in claim 1 or 2, wherein the functional and / or therapeutic agent comprises a drug selected from the group consisting of adhesives, healing agents, and functional or therapeutic drugs.

4. Further comprising a first sheath and an inner member; the stent is disposed about the inner member; 3. The system of claim 1, wherein the first sheath is longitudinally retractable proximally relative to the inner member, or the inner member is longitudinally extendable distally relative to the first sheath, or both, such that the stent is released from within the first sheath and transitions to the second configuration.

5. The system described in claim 4, further comprising a cutting element disposed at an end of the inner member.

6. Further comprising a second sheath disposed on the first sheath; the second sheath is longitudinally retractable proximally relative to the inner member, or the inner member is longitudinally extendable distally relative to the second sheath, or both; 5. The system of claim 4, wherein the system is configured to deploy the functional and / or therapeutic agent on the surface of the stent when the second sheath is retracted proximally relative to the inner member, or when the inner member is extended distally relative to the second sheath, or both.

7. A system as described in claim 1 or 2, wherein the system is configured to position the functional and / or therapeutic agent when pressure is applied to the functional and / or therapeutic agent from the proximal end of the system.

8. The system described in claim 6, wherein the functional and / or therapeutic agent comprises a first functional and / or therapeutic drug component and a second functional and / or therapeutic drug component, the first component and the second component being configured to react upon contact with each other.

9. The system described in claim 8, wherein the first functional and / or therapeutic drug component is disposed between the first sheath and the second sheath, and the second functional and / or therapeutic drug component is disposed on the stent when disposed within the first sheath.

10. A system as described in claim 1 or 2, wherein the first retaining member and the second retaining member are configured to separate a portion of the tissue wall from the saddle region.

11. The system described in claim 1 or 2, further comprising a fluid delivery device configured to inject the functional and / or therapeutic agent.

12. The system of claim 11, wherein the fluid delivery device is configured to inject the functional and / or therapeutic agent through a portion of the tissue wall into a volume defined by the stent and a portion of the tissue wall.

13. The system of claim 12, wherein the fluid delivery device is configured to extend through one of the first retaining member or the second retaining member to inject the functional and / or therapeutic agent into the volume defined by the stent and a portion of the tissue wall.

Images